3-(3-(2,10-dichloro-5,7-dihydroindolo[2,3-b]carbazol-6-yloxy)propyl)pyrimidine-2,4(1H,3H)-dione | 1217107-64-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 3-(3-(2,10-dichloro-5,7-dihydroindolo[2,3-b]carbazol-6-yloxy)propyl)pyrimidine-2,4(1H,3H)-dione
• 英文别名: 3-[3-[(2,10-dichloro-5,7-dihydroindolo[2,3-b]carbazol-6-yl)oxy]propyl]-1H-pyrimidine-2,4-dione
• CAS: 1217107-64-6
• 化学式: C₂₅H₁₈Cl₂N₄O₃
• 分子量: 493.349
• InChiKey: QTYSKTALGCIABM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.4
• 重原子数：
  34
• 可旋转键数：
  5
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  90.2
• 氢给体数：
  3
• 氢受体数：
  3

文献信息

• Analogs of Indole-3-Carbinol and Their Use as Agents Against Infection
  申请人：Jong Ling

  公开号：US20100069355A1

  公开（公告）日：2010-03-18

  Compounds useful as antibacterial agents are provided. The compounds are analogs of indole-3-carbinol and have a backbone selected from dihydroindolo[2,3-b]carbazole, 2,2′-diindolylmethane, 2′,3-diindolylmethane, and 3,3′-diindolylmethane. The compounds are useful therapeutic and prophylactic treatment of bacterial infections in mammals. Methods of synthesis of the compounds are provided, as are pharmaceutical compositions containing the compounds.

  提供了作为抗菌剂有用的化合物。这些化合物是吲哚-3-甲醇的类似物，具有从二氢吲哚并[2,3-b]咔唑，2,2′-二吲哚甲烷，2′,3-二吲哚甲烷和3,3′-二吲哚甲烷中选择的骨架。这些化合物对哺乳动物的细菌感染的治疗和预防治疗有用。提供了合成这些化合物的方法，以及含有这些化合物的药物组合物。
• Lipoxygenase inhibitors
  申请人：SRI International

  公开号：US10646471B2

  公开（公告）日：2020-05-12

  The disclosure provides bisindole suitable for inhibiting lipoxygenases or Aβ-formation, and treating associated diseases, such as Alzheimer's disease. The bisindoles are indolo[2,3-b]carbazole derivatives, and may be administered to a patient as part of a pharmaceutical formulation.

  本公开提供了适用于抑制脂氧合酶或 Aβ 形成以及治疗相关疾病（如阿尔茨海默病）的双吲哚。双吲哚是吲哚并[2,3-b]咔唑衍生物，可作为药物制剂的一部分施用给患者。
• ANALOGS OF INDOLE-3-CARBINOL AND THEIR USE AS AGENTS AGAINST INFECTION
  申请人：SRI International

  公开号：EP2326327B1

  公开（公告）日：2016-03-23
• LIPOXYGENASE INHIBITORS
  申请人：SRI International

  公开号：EP2694057B1

  公开（公告）日：2019-06-05
• Lipoxygenase Inhibitors
  申请人：SRI International, Inc.

  公开号：US20130345214A1

  公开（公告）日：2013-12-26

  The disclosure provides bisindole suitable for inhibiting lipoxygenases or Aβ-formation, and treating associated diseases, such as Alzheimer's disease. The bisindoles are indolo[2,3-b]carbazole derivatives, and may be administered to a patient as part of a pharmaceutical formulation.